best-in-class lead asset
initi ow
differenti fcrn strong
toler profil coupl competit efficaci see
proof-of-concept data gmg itp derisk pipelin
solid data broader pipelin
remain mani driver upsid
anti-fcrn offer signific opportun best-in-class asset
mani compani work anti-fcrn antibodi given multitud
autoimmun diseas igg lower could impact see among
best-in-class asset particular believ safeti affin durabl
differenti current see key indic gener
myasthenia gravi gmg primari immun thrombocytopenia itp
pemphigu vulgari pv provid greater market opportun
argenx could see sale current enrol
phiii studi gmg data expect underlin signific
derisk alreadi occur
initi data gmg itp derisk opportun importantli
alreadi demonstr proof-of-concept limit potenti
downsid initi dataset gmg itp confirm competit efficaci
profil less headach diarrhea agent despit greater
exposur importantli believ ph determin affin profil
support differenti profil includ durabl safeti
offer second upsid driver valid partnership
updat data demonstr high rate complet respons hard
treat aml strong data coupl management broad partnership
cover david lewi provid second import asset see aml
potenti peak sale opportun consensu valu
breadth clinic program reveal
progress gmg itp phiii studi initi pv data updat
drive argx remain mani key catalyst includ
initi data pv phiii start itp potenti updat
subcutan dose believ breadth clinic plan
expect allow investor fulli valu asset
continu see clinic data key driver argx
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
safeti efficaci data mg itp pv drive risk/reward
safeti efficaci data mg itp pv
pt deriv dcf use
discount rate termin growth rate revenu driver
model
commerci strong uptak bull case
valu risk adjust vari
product launch begin
respect gener sale
argenx success commerci base
case valu mg itp pv aml ctcl risk adjust vari
product launch begin
respect gener sale
fail argenx unabl commerci argx trade
overweight thesi base
success commerci
sever compani develop anti-
fcrn antibodi treatment
autoimmun diseas mani compani
report safeti and/or reduc efficaci
compar
design uniqu ph-
depend bind profil extend
therapeut durabl fewer report
advers event compar compet anti-
diseas indic demonstr
efficaci safeti
demonstr clinic
activ aml
phiii data gmg demonstr
differenti safeti efficaci
phii data pv itp also
phii data pv expect phiii
data gmg expect
demonstr efficaci aml
risk achiev price
signal would like caus investor
question differenti valu
reduc efficaci
delay timelin posit data
competitor could weight
market share especi competitor data
arriv new indic prior pivot
effect treat
refractori aml patient compar
standard care
initi coverag argenx pt overweight rate agenx
develop novel antibodi autoimmun diseas cancer lead asset
anti-fcrn antibodi gener proof concept data
gener myasthenia gravi gmg primari immun thrombocytopenia itp
believ data-to-d significantli derisk suggest could
best-in-class anti-fcrn expect phiii data gmg on-go adopt studi
avail point overweight thesi includ
potenti best-in-class profil mani compani work anti-fcrn
includ alexion ucb cover momenta cover base review
data believ argenx cleaner safeti especi headach diarrhea
efficaci see strong profil igg reduct in-line agent
along favor dose profil final ph bind affin profil
support molecul differenti believ affin profil
prevent accumul cell consequ improv stabil durabl
support phii data broad phii data gmg itp support profil
gmg itp igg level lower sustain dose
period studi demonstr clear efficaci favor given
robust set data see strong market share expect clean phiii
studi indic current risk-adjust gmg
exhibit clinic meaning improv gmg
exhibit platelet count improv itp
signific opportun beyond includ recent data
valid orr cr rate includ partnership
 allow management prosecut broad develop strategi liquid tumor aml
md indic believ maxim opportun
see potenti un-risk-adjust peak sale high
remain key year catalyst see regulatori clariti itp initi pv data
full clinic plan aml major event could drive argx higher
present valu million
discount cf
price target includ risk adjust peak revenu deriv
price target discount cash flow dcf analysi use wacc
valuat methodolog prefer use dcf analysi valu biotechnolog
compani given defin patent live believ dcf
fulli captur up-front invest period well long-term earn
power investor look biotechnolog multipl basi price-to-earnings prefer
dcf rigor requir explicit assumpt long-term
prospect compani
discount rate util discount rate argenx compani
clinic stage develop coverag util discount rate
commerci compani rate compani random phii data
rate develop stage compani
termin growth rate model explicit revenu assum
revenu includ risk-adjust revenu valuat valu
argenx main asset treatment mg itp pv project revenu begin
grow also valu
treatment aml project revenu begin grow
econom argenx maintain world-wide right argenx partner
develop establish profit share agreement us
royalti payment outsid us
cog estim cog sale model cog grow
oper expens project grow
argenx invest commerci multipl product candid invest
 level thereaft spent model
grow commerci first product
near gradual growth thereaft
risk price target includ poor safeti and/or efficaci data argx-
late stage clinic trial lead investor question asset delay
develop commerci provid opportun
competition reach market first inferior safeti and/or efficaci argx-
treatment aml compar standard care
overview argenx develop novel anti-fcrn antibodi treat
autoimmun diseas block fcrn gener promis initi data rang
autoimmun diseas safeti could key factor differenti
compet antibodi demonstr uniqu bind affin
fcrn believ extend drug durabl improv safeti
profil compet clinic stage anti-fcrn antibodi report advers side
effect includ reduct albumin higher rate headach diarrhea
compar
street take investor appreci clinic success date
focus see phiii data larger patient popul support drug
efficaci differenti safeti profil
take demonstr proof-of-concept gener myasthenia
gravi gmg immun thrombocytopenia itp base phii clinic trial
continu demonstr efficaci fewer side effect phiii trial
believ captur signific share igg-medi autoimmun
diseas market see peak sale base case
role fcrn igg homeostati
neonat fc receptor fcrn serv multipl transport role throughout bodi
sever compani develop therapi inhibit function role fcrn
first implic transfer passiv humor immun mother
fetu context fcrn express epitheli cell lung intestin facilit
unidirect transfer mother antibodi igg babi bloodstream
fcrn also express vascular endothelium main site igg
recycl target therapeut intervent cellular level igg
albumin taken cell fluid-phas pinocytosi bind fcrn mhc
class i-rel receptor express endosom unbound ligand traffick
lysosom degrad igg albumin bound fcrn recycl back
circul illustr bind affin fcrn depend ph allow
fcrn bind acid condit endosom releas ligand
expos physiolog ph blood
exhibit fcrn mechan action
roopenian akilesh fcrn neonat fc receptor come age natrevimmunol
system target treat autoimmun diseas gener caus
either excess express defect elimin antibodi healthi tissu
argenx develop anti-fcrn antibodi block igg bind decreas
overal concentr igg circul block fcrn valid approach
treat sever orphan indic includ myasthenia gravi immun
thrombocytopenia myasthenia gravi mg exampl rare autoimmun diseas
character pathogen antibodi target acetylcholin receptor muscle-
specif receptor tyrosin kinas diseas neuromuscular junction lead
skelet muscl weak mg affect peopl us current
treat cholinesteras inhibitor corticosteroid immunosuppress ivig
plasmapheresi soliri termin complement inhibitor thymectomi minor
patient ivig plasmapheresi soliri expens therapi cost
approxim respect immun
thrombocytopenia itp anoth autoimmun diseas caus autoantibodi
platelet antigen lead low platelet count thrombocytopenia itp affect
peopl us symptom rang mild bruis sever bleed
tpo mimetics/splenectomi romiplostim eltrombopag last line therapi
gener global revenu respect mg itp
autoimmun diseas repres indic compet anti-
fcrn antibodi target demonstr respect efficaci
differ competit
sever compani develop anti-fcrn antibodi differenti
base superior safeti efficaci data support uniqu ph-depend
bind profil tabl summar key properti antibodi
advanc molecul left section highlight properti
differenti competit overal see differenti across
safeti efficaci durabl
exhibit compar competit
safeti multipl clinic trial across differ diseas indic support favor
safeti profil compar anti-fcrn antibodi well
toler fewer advers event includ headach diarrhea also
evid suggest reduc albumin level report
common side effect block fcrn
efficaci demonstr superior equal efficaci competit
molecul across sever clinic trial head-to-head comparison diseas relat
biomark reduct igg level highlight uniqu durabl biolog
activ
durabl obviou properti differenti reduc bind
affin ph lower compet antibodi time higher
endogen igg uniqu affin profil explain bind
natur interact site fcrn compar antibodi bind
variabl domain lead conform chang receptor advantag
paradigm may counterintuit sever report literatur
suggest increas affin near-neutr ph actual increas degrad
accumul cell consequ decreas half-lif antibodi
exampl bottom left figur compar ph-depend bind profil two
antibodi harbor differ mutat nse-yt yte demonstr
high affin bind ph yte high affin bind ph
reduc bind ph bottom right figur reflect serum level
antibodi hfcrn transgen mous model antibodi clear
significantli higher rate yte antibodi support downsid increas
bind neutral condit suggest affin profil prevent
accumul cell consequ improv stabil durabl
summari preclin develop
compani develop anti-fcrn antibodi expand upon year
foundat work publish primari literatur section briefli
summar preclin data present argenx support mechan action
potenti efficaci antibodi
antibodi fc-fragment acquir argenx base preclin
studi lab professor salli ward univers texa southwestern
medic center dr ward increas bind affin human fcrn
ph mutat five amino acid fc region mutat
becam foundat argenx proprietari abdeg platform effect
mst-hn circul igg level initi demonstr mous model one
studi measur concentr radiolabel human administr
two differ dose mst-hn graph bottom left show
mst-hn significantli reduc level circul radiolabel
second studi measur endogen igg level mst-hn
inject inhibit fcrn reduc total igg concentr vivo
vaccaro zhou ober ward engin fc region immunoglobulin modul vivo antibodi level
compar clinic data
clinic trial data relat advanc anti-fcrn antibodi summar
main take-away section compet antibodi
demonstr efficaci phi and/or phii clinic trial data support
therapeut potenti block fcrn treat rang igg-medi autoimmun
argenx complet phi singl sad multipl ascend dose mad studi
healthi volunt singl multipl dose mg/kg well-toler
signific reduct igm/iga albumin level report bottom left
figur singl dose arm demonstr maximum igg reduct low
igg level maintain four week one dose figur
right multipl ascend dose arm demonstr total igg
reduct reduct last approxim three week eventu
return baselin one month
exhibit phi mad sad data
phii studi mg patient compar standard care mg/kg
standard care plu placebo patient receiv four dose three week
follow eight week mg-adl score use measur
efficaci provid assess mg symptom sever two point increas
mg-adl score indic clinic meaning improv phii studi
report patient receiv achiev clinic meaning
improv treat patient maintain improv least six
consecut week bottom left figur total igg level also reduc level
seen phi studi bottom right figur note igg reduct
seen across igg subtyp includ pathogen acetylcholin receptor
autoantibodi muscle-specif kinas autoantibodi
itp phii studi evalu safeti platelet count correl autoantibodi
level phii trial enrol itp patient random receiv four weekli dose
mg/kg mg/kg standard care compar standard care
plu placebo well-toler patient post-hoc analysi around
platelet count use rescu treatment report regard durabl
patient clinic meaning platelet respons /l two
visit mean durat day compar day placebo
treat patient patient rapid deep reduct total igg
level consist previou trial graph
momenta also test phi healthi volunt studi design singl
multipl ascend dose arm reduc igg level less one week
report well toler sae individu reach
reduct igg bottom left figur show dose respons sad cohort
bottom right figur show approxim reduct serum igg percent
baselin note four dose mg/kg demonstr
similar reduct serum igg level compar four mg/kg dose
ucb pharma test subcutan administr human
antibodi patient primari itp phii studi split patient
receiv mg/kg week five week patient receiv mg/kg
week three week patient follow eight week last dose
frequent teae headach one patient mg/kg group report
ctcae grade headach mg/kg cohort maximum
mean decreas igg day day respect bottom left figur clinic
relev improv platelet count report patient
treatment arm bottom right figur
ucb pharma recent report phii trial test subcutan administr
mg patient studi broken two dose phase mg
patient us europ enrol first dose phase compar three
weekli dose mg/kg placebo four week patient treat
experienc reduct serum igg igg autoantibodi mg-
adl respond rate compar placebo patient
re-random receiv three weekli dose mg/kg mg/kg
patient receiv mg/kg dose phase experienc reduct
total igg anti-acetylcholin receptor autoantibodi full data set
present upcom medic confer base mg-adl respond rate four
dose mg/kg slightli superior three dose
mg/kg signific conclus realiz compar
frequenc headach patient receiv total mg/kg
experienc headach compar patient receiv mg/kg
first dose phase go detail safeti profil drug
alexion recent acquir syntimmun intent develop
human antibodi treat pemphigu warm autoimmun hemolyt anemia
waiha pemphigu caus igg autoantibodi desmoglein dsg
lead pain lesion interim analysi phib multiple-ascend dose studi
activ pemphigu vulgari foliaceu provid evid safeti
efficaci patient receiv five weekli dose mg/kg
follow day total igg circul immun complex cic measur
along pdai potenti diseas specif biomark reduc mean total
igg mean cic level bottom left figur bottom right figur
demonstr correl igg/cic mean pdai score reduc
day data support fcrn valuabl target treat
diseas caus autoantibodi
lead safeti
base earli stage clinic data favor safeti profil compar
occurr headach diarrhea known side
effect igg modul therapi given fcrn express endotheli cell
line gut blood vessel chart summar rate headach
diarrhea clinic trial rang phi phii
 report highest rate treatment emerg advers event teae
patient report headach respect phii studi
report higher rate headach diarrhea compar
comparison signific given patient receiv one addit dose
higher concentr mg/kg vs mg/kg compar reduct
albumin level also consid common side-effect anti-fcrn therapi
evid suggest reduc albumin level momenta
report reduct albumin phi reduct albumin seen
mg/kg single-ascend dose mg/kg dose
multiple-dos cohort addit patient mg/kg multiple-
ascend dose cohort report elev creatin kinas level muscl fda
express concern relat effect monitor go forward
data support differenti safeti profil compar
efficaci compar across molecul
molecul develop demonstr signific reduct
circul igg level sever includ report clinic
improv point clinic develop difficult compar efficaci
given small sampl size advanc
demonstr similar efficaci itp patient initi platelet count improv
similar phii interim analysi chart point
view efficaci truli differenti factor
debat opportun fcrn much share
overview argenx enter competit market alongsid sever anti-
fcrn molecul advanc commerci anti-fcrn
molecul phiii develop argenx establish clear path reach
approv least three indic includ gmg itp pv section
discuss competit clinic timelin potenti opportun
path market
street take investor familiar igg mediat orphan diseas
appreci upsid target approach investor focus futur
clinic data support clearli differenti profil overal see
greatest debat around commerci profil asset emerg
enough differenti among asset support upsid
market share singl asset
take see clear leader among fcrn candid
importantli believ achiev lead market share gmg itp given
differenti clinic profil view market size base
case potenti much sale argenx
potenti market anti-fcrn drug deriv success ivig
therapi subpopul autoimmun diseas anti-fcrn therapi block igg
bind fcrn consequ shuttl igg lysosom degrad ivig
therapi act flood system igg dilut pathogen antibodi
mg itp chronic inflammatori demyelin polyradiculoneuropathi cidp
multifoc motor neuropathi mmn specif igg mediat diseas
current manag ivig could possibl treat anti-fcrn therapi
hemolyt diseas fetu newborn hdfn warm autoimmun hemolyt
anemia waiha addit indic compet anti-fcrn compani
target success ivig plasmapheresi therapi igg mediat
diseas provid valid path commerci anti-fcrn therapi
differenti current standard care target mechan
action potenti favor safeti durabl profil
american academi neurolog confer argenx report phii data
investig safeti efficaci patient diagnos mg
studi demonstr proof concept target engag efficaci potenti
differenti safeti profil total patient enrol trial
treat mg/kg standard care standard care alon
patient receiv four dose three week follow eight week
demonstr efficaci reduct pathogen igg correl
diseas score improv
argenx also complet phii studi refractori patient itp compar
mg/kg mg/kg plu standard care standard care alon argenx
present full data demonstr favor safeti
profil meaning platelet count improv compar standard care
new patient includ present one patient began
respond mg/kg respond mg/kg consist trial
reduct igm iga albumin report patient treat dose
experienc improv platelet count /l least two visit
report improv open-label extens arm report
sever bleed patient treatment arm experienc least one
bleed teae compar placebo cohort emphas physician
field believ rate teae consist manag patient itp
base posit result argenx plan launch phiii studi itp iv
phii proof concept studi chronic immun demyelin polyneuropathi cidp
near futur
pivot program mileston
phiii expect enrol patient gmg us europ japan patient
receiv placebo mg/kg iv primari endpoint
efficaci determin myasthenia gravi activ daili live mg-adl score
secondari endpoint includ safeti toler qualiti life phiii
studi design registr trial support submiss biolog licens
applic us market author japan
studi start expect enrol month
hope learn would provid investor addit convict
efficaci well toler patient mg improv
mg-adl score could provid compar evid support differenti
profil random phiii significantli power provid
investor enough confid support efficaci anti-fcrn gmg
phii expect enrol patient moder pv newli diagnos
relaps germani hungari israel itali ukrain primari goal studi
evalu safeti toler includ incid sever teae sae
secondari endpoint assess pk/pd efficaci pdai time diseas control time
relaps immunogen non-control adapt design first
cohort patient follow week screen period induct treatment period
week mainten treatment period week follow-up period week
patient receiv weekli dose indic period two addit
mainten dose week last induct dose cohort
includ addit patient test maximum dose mg/kg addit dose
induct period expans mainten durat relaps
defin three lesion appear within month heal within
week establish lesion heal
hope learn studi provid valuabl inform futur
trial includ pivot phiii given patient enrol investor
focus safeti evid diseas control treatment
argenx report posit result phii proof-of-concept trial primari itp
prepar initi pivot phiii studi test iv subcutan
administr argenx current discuss fda determin
design trial test safeti efficaci administr routin
patient itp anticip start trial
competit clinic program mileston
momenta recent report first-in-human data healthi volunt
support initi phii trial sever hemolyt diseas newborn hdfn
gmg phii gmg enrol patient test optim dose schedul
expect report top line result momenta also initi phii trial hdfn
follow regulatori accept canada posit opinion uk spain
netherland belgium momenta continu talk fda file ind
us anticip proof concept
ucb pharma report phii data gmg itp management explicit
plan ucb plan initi phii trial chronic inflammatori
demyelin polyneuropathi cidp confirmatori studi mg start
would expect second anti-fcrn antibodi enter phiii
alexion enrol patient chronic stabl warm autoimmun hemolyt anemia
waiha phib/iia trial test two differ iv dose primari
endpoint safety/toler day secondari outcom measur
includ serum concentr hematocrit/hemoglobin level
hope learn studi provid insight safeti efficaci
waiha studi success alexion plan move
pivot studi posit first approv therapi waiha
anticip alexion report phib/ii data pemphigu vulgari foliaceu
patient receiv iv primari endpoint safety/toler
day secondari outcom measur includ serum concentr
pemphigu diseas area index pdai data defin
competit landscap provid investor clearer understand
argenx enter competit autoimmun diseas market current approv
therapi plasma-deriv ig gener global revenu argenx initi
test mg itp pv repres pivot indic affect
peopl us respect success
indic provid support expand orphan autoimmun diseas
could significantli expand market competit anti-fcrn antibodi
also advanc clinic develop could affect market
share futur anticip signific impact revenu
expect price us similar
antibodi base therapi orphan indic gmg market model anticip
us launch detail assumpt use reach peak global sale
exhibit itp market model exhibit anticip launch
peak sale pv market model exhibit anticip
launch peak sale three indic repres
part larger autoimmun diseas market could benefit anti-fcrn
patient
probabl success
patient
probabl success
patient
probabl success
patient
probabl success
patient
probabl success
patient
probabl success
debat get els
overview manag recent enter partnership janssen
develop cusatuzumab treatment aml md
section review collabor agreement mechan
action recent clinic data partnership develop statu
remain asset pipelin also highlight section
street take investor encourag collabor agreement
janssen wait see addit evid phi/ii aml studi
support potenti efficaci believ investor
assign appreci valu rel low probabl
success given complex competit aml develop field
take view partnership janssen phi/ii clinic trial result
encourag evid support potenti efficaci believ
becom key asset argenx assign rel modest
probabl success given earli data
argenx enter global collabor licens agreement johnson johnson
develop collabor leverag commerci expertis
janssen advanc aml md hematolog malign
janssen paid up-front purchas newli issu share argenx
option receiv mileston tier double-digit royalti split
develop cost janssen handl larger share
highlight argenx share us market repres signific
clinic develop
antitumor defucosyl monoclon antibodi act immun
checkpoint blockad enhanc antibody-depend cell-medi adcc
cytotox specif develop treat sever subtyp non-
hodgkin lymphoma involv b-cell t-cell immun checkpoint blockad
mediat overexpress solid hematolog tumor regulatori
cell treg express receptor bind lead treg activ
activ treg creat immune-suppress microenviron allow
prolifer surviv tumor cell enhanc adcc achiev argenx
potellig engin technolog modul fc region
antibodi modif increas potenti natur killer cell invad
tumor microenviron similar immun modul therapi
design prevent treg activ restor immun surveil also
enhanc potenti natur killer nk cell induc cytotox
interact implic earli diagnosi acut myeloid
leukemia aml bind caus cleavag extracellular
portion lead solubl form molecul solubl elev
aml patient bottom left figur predict poor prognosi bottom right
preclin studi demonstr efficaci aml
xenotranspl mous model achiev engraft differ
aml patient cell immunodefici mice mice treat either mg/kg
control antibodi waterfal plot demonstr
surviv benefit inhibit far right figur highlight reduct solubl
level treatment support defin mechan
action reliabl biomark
base data argenx initi phi/ii trial test azacitidin aza
newli diagnos aml patient qualifi intens chemotherapi
ration behind combin therapi support dna hypomethyl agent
aza upregul primari human aml leukemia stem cell potenti
lead therapi resist patient trial receiv two week lead-in
mg/kg everi two week combin aza present
orr patient patient reach cr/cri
respons rate correl decreas blast bone marrow reach
reduct monotherapi best respons level median durat
respons month patient continu trial one
year combin therapi well toler report dlt grade
hematolog toxic relat aza manag plan use mg/kg
phii studi orr support differenti approach treat aml
continu focu durabl safeti studi continu manag
anticip report full phii data
argenx also initi phi/ii trial test advanc cutan
t-cell lymphoma ctcl total patient diseas stage enrol
advanc ctcl differ subtyp mf ss sptcl fth alcl
given iv mg/kg phi mg/kg
phii manag report orr cr pr cr pr
sd patient still studi mean durat trial end
treatment month overal favor safeti profil observ
repres second revenu gener asset factor
overal valuat argenx base continu clinic success anticip
launch reach peak risk adjust sale given
complex competit checkpoint inhibitor space assign
probabl success expect greater resolut around target patient
popul aml md patient receiv
patient
probabl success
profit share
patient
probabl success
royalti
addit asset partnership statu
pipelin chart summar key product candid advanc
preclin earli clinic develop overal manag go immun
mediat indic advanc antibodi develop platform sever
candid partner collabor agreement describ
argenx develop treat autoantibodi complement-medi
disord potenti act synergist argenx exercis
option licens broteio innov access program
allow collabor use antibodi technolog discov novel target argx-
design proprietari fc engin technolog nhanc introduc
two mutat extend antibodi serum half-lif increas tissu
penetr manag anticip releas inform
 day
gerilimzumab monoclon antibodi block signal
decreas inflammatori respons rheumatoid arthriti also
design nhanc technolog extend antibodi serum half-lif tissu
argenx receiv mileston payment bird termin licens
agreement genor pharma sublicense bird continu
develop chines market
design treat inflammation-bas dermatolog indic
leo pharma respons fund develop cost clinic
trial applic cta approv first phi trial europ base term
deal argenx elig mileston payment tier
royalti leo pharma paid third preclin mileston payment upon cta
approv
novel immuno-oncolog antibodi target glycoprotein
repetit predomin regul transform growth factor beta
tgf- stimul immun system attack cancer cell block
immunosuppresss activ regulatori t-cell treg
recent exercis option licens make argenx
elig develop regulatori commerci mileston payment
addit tier royalti product sale
antibodi design treat dyslipidemia
staten respons clinic develop cost argenx elig
royalti low twenti
euro million
sale
research develop
sell gener administr
oper expens
euro million
cash equival
research develop incent receiv
trade receiv
research develop incent receiv
properti equip net
trade payabl
provis employe benefit
total liabil stockhold equiti
euro million
adjust reconcil net loss net cash use oper activ
depreci properti plant equip
amort intang asset
loss dispos fix asset
provis employe benefit
expens recogn respect sharebas payment
chang oper asset liabil
trade receiv
trade payabl
net cash use oper activ
purchas properti equip
purchas intang asset
increas /decreas current financi asset
net cash use invest activ
proce issu share
transact cost equiti issu
net cash provid financ activ
net increas decreas cash cash equival
cash equival begin period
cash equival end period
